Hepatitis virus infection is a serious public health problem and the cost of treating chronic hepatitis is quite expensive. Hepatitis B and C cause up to 80% of liver cancer deaths and hepatitis C virus (HCV) has become the leading cause of liver-related morbidity and mortality worldwide. HCV is known as one of the most dangerous diseases. In recent years, vaccines against hepatitis A and B and the use of various antiviral drugs have been effective in controlling hepatitis virus infection. However, these drugs have also led to the emergence of hepatitis C virus variants. To date, there is still no vaccine that can protect viral hepatitis C. In addition, currently available direct-acting antiviral drugs (DAAs) against HCV are ineffective against all genotypic variants of the virus, and the resistance against drugs in clinical use will eventually emerge. Researchers worldwide are therefore searching for antiviral drugs with new structures and mechanisms of action in hepatitis C.
BOC Sciences has designed its anti-HCV library containing more than 1,600 compounds.
Figure 1. High-throughput screens to identify compounds that inhibit HBV. (Xia, Y.; Liang, T. J. 2018)
All compounds show desired activity against the following Hepatitis C virus genotypes and their targets:
BOC Sciences provides professional, rapid and high-quality services of Anti-hepatitis Screening Library design at competitive prices for global customers. Personalized and customized services of Anti-hepatitis Screening Library design can satisfy any innovative scientific study demands. Our clients have direct access to our staff and prompt feedback to their inquiries. If you are interested in our services, please contact us immediately!
Reference
BOC Sciences has rich experience in working with global customers in custom library synthesis of compounds and generating small to medium-sized libraries of target compounds. Our knowledge in generating a large number of target molecules in a remarkably shorter time enables quick biological screenings for affinities. With the target properties in mind, we deliver target molecules, by applying our extensive knowledge in drug discovery.